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0929-6646/Copyright ª 2015, ElsevierBackground/Purpose: Interleukin (IL)-17 family members (IL-17A to IL-17F) are appearing to
play key roles in host defense and inflammatory disease. Recently, several cytokines, such
as IL-6, IL-10, IL-12, and transforming growth factor (TGF)-b1, were shown to have vital roles
in severe sepsis. However, the influence of IL-17 on these cytokine responses from peripheral
blood mononuclear cells (PBMCs) is unclear.
Methods: Fifty-two patients who were admitted to our intensive care unit (ICU) because of se-
vere sepsis were enrolled into this study. To validate experimental findings, 25 healthy controls
were enrolled. Lipopolysaccharide-stimulated PBMCs with IL-17 or anti-IL-17 treatments were
cultured for 24 hours. IL-6, IL-10, IL-12, and TGF-b1 levels in supernatants were measured.
Results: The IL-12 production from stimulated PBMCs was increased after IL-17 treatment in
both control and patient groups. Additional treatment of anti-IL-17 enhanced IL-10 production
but decreased IL-12 production from stimulated PBMCs of healthy controls and patients with
severe sepsis.
Conclusion: IL-17 was helpful for inflammation in severe sepsis. Lack of IL-17 decreased IL-12
and enhanced IL-10 production from PBMCs, which resulted in immune imbalance.
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Severe sepsis is the first cause of death in medical intensive
care units (ICUs). It is now thought that a hyperinflammatory
response at the beginning is designed to eradicate the
pathogens and immune dysfunction results in death.1e3 The
peptidoglycan of gram-positive bacteria can bind to toll-like
receptor (TLR)-2 and the lipopolysaccharide (LPS) of gram-
negative bacteria binds to TLR-4. In immune cells, cyto-
solic nuclear factor kappa-B (NF-kB) is activated through
TLR-2 and TLR-4, and this enhances cytokine production.
CD4þ T help cells play an important role in severe sepsis.
Naı¨ve CD4þ T helper (Th) cells now can differentiate toward
Th1, Th2, Th17, and regulatory T (Treg) phenotypes accord-
ing to different cytokine induction.4 A combination of
interleukin (IL)-6 and transforming growth factor (TGF)-b
skews toward Th17.5 Th17 cells can produce IL-17A and IL-
17F, which behaves as a potent inflammatory cytokine.6
Many cells express IL-17A and IL-17F including Th17 cells,
natural killer (NK) cells, mast cells, and neutrophils. Th17
cells are the main cells to produce IL-17A and IL-17F.7 IL-17
family members (IL-17A to IL-17F) also play key roles in host
defense and inflammatory disease.
IL-17A and IL-17F can promote innate immunity by trig-
gering proinflammatory cytokine response. IL-17 stimulated
human macrophages to produce and express IL-b and tumor
necrosis factor (TNF)-a.8 Recently, Flierl et al9 reported an
important animal study. They found that neutralization of
IL-17 improved sepsis. It still worked even though the anti-
IL-17A administration was delayed for 12 hours. Further-
more, IL-17 antagonist significantly suppressed plasma TNF-
a, IL-1b, and IL-6 levels, and increased plasma IL-10 and
TGF-b levels after cecal ligation and puncture (CLP). IL-17
stimulated lung endothelial cells to produce IL-8, which
enhance neutrophil but not lymphocyte chemotaxis.10
Moreover, IL-17 activated endothelial cells by way of the
endothelial adhesion marker expression in a p38 mitogen-
activated protein kinase-dependent pathway.
Recently, several cytokines, such as IL-6, IL-10, IL-12,
and TGF-b1, showed vital roles in severe sepsis.11e13
Plasma IL-6 and TGF-b1 levels were associated with dis-
ease severity. Plasma IL-10 levels and restored IL-12 re-
sponses from peripheral blood mononuclear cells (PBMCs)
were associated with mortality. However, the effect of IL-
17 on these cytokine responses from PBMCs remains un-
clear. Thus, an in vitro human study was designed to
address this and to answer this question. LPS was used as a
stimulator because most pathogens in severe sepsis are
gram-negative bacteria.
Materials and methods
Study participants
From August 2009 to July 2011, 52 patients with severe
sepsis were enrolled in this study after admission to our
ICU. Patients with high-dose corticosteroid use, neu-
tropenia, and human immunodeficiency virus infection
were excluded. Severe sepsis was defined according to the
consensus criteria.3,14 Disease severity was evaluated by
the Acute Physiology and Chronic Health Evaluation(APACHE) II score.15 All patients were treated according to
guidelines.16,17 Informed consent was provided by a close
family member. This investigation (97-2179B) was approved
by the Institutional Review Board at Chang Gung Memorial
Hospital, Keelung, Taiwan. All comorbidities and histories
of the study participants were recorded. Survivors were
defined as alive for 28 days. For validating experimental
findings, 19 men and 6 women were enrolled as healthy
controls from the individuals at health evaluation center.
Plasma and PBMCs preparation
Briefly, 10 mL of whole blood was sampled within 48 hours
from each patient and mixed with heparin immediately.
Plasma from 2 mL of whole blood was obtained, and stored
at 80C. The PBMCs were separated from residual 8 mL of
whole blood by the differential centrifugation using Ficoll-
Plaque (Amersham Biosciences, Uppsala, Sweden) within 2
hours.
Flow cytometric analysis of PBMCs
Flow cytometry to detect monocytes, CD4þ lymphocytes,
CD8þ lymphocytes, Th1 cells, Th2 cells, Th17 cells, and Treg
cells was performed according to our previous pro-
tocols.12,18 Data were analyzed with Kaluza software
version 1.1 (Beckman Coulter, Brea, CA, USA).
Cell culture
The 5  105 PBMCs were plated in four wells of a flat-
bottomed 24-well plate (Nunclon, Aarhus, Denmark) in
1 mL sterile Roswell Park Memorial Institute (RPMI) 1640
tissue culture medium containing 5% heat-inactivated
bovine serum, 1 mM of L-glutamine (Gibco, Grand Island,
NY, USA) and 1 mM sodium pyruvate. The cells in the first
well (C group) were not stimulated. The cells in the second
well (LPS group) were stimulated with 1 pg/mL LPS (Sigma-
Aldrich, St. Louis, MO, USA). The cells in the third well
(LPS þ anti-IL-17 group) were stimulated with 1 pg/mL LPS
and treated with 12,500 pg/mL of neutralizing monoclonal
anti-human IL-17A antibody (eBioscience, San Diego, CA,
USA). The dose of neutralizing monoclonal anti-human IL-
17A is based on our previous work that showed the range of
IL-17 response was 0-47.3 pg/ml.12 The cells in the fourth
well (LPS þ rhIL-17 group) were stimulated with 1 pg/mL
LPS and treated with 100 pg/mL of recombinant human (rh)
IL-17A/F (eBioscience). The plate was incubated at 37C in
5% CO2 for 24 hours. Supernatants of the culture wells were
retrieved and stored at 80C.
Cytokine measurement
IL-10 levels in supernatants were assessed with a human
enzyme-linked immunosorbent assay (ELISA) kit (Pierce
Biotechnology, Rockford, IL, USA), according to the manu-
facturer’s instructions. IL-6 and TGF-b1 levels in superna-
tants were assessed with human ELISA kits (R&D Systems,
Inc., Minneapolis, MN, USA). IL-12 levels of supernatants
were assessed with a human ELISA kit (Becton Dickinson,
San Jose, CA, USA).
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Data were analyzed using SPSS version 17.0 for Windows
(SPSS Inc., Chicago, IL, USA). Differences for continuous
variables between survivors and nonsurvivors were
analyzed by ManneWhitney U test. Differences of cate-
gorical variables were compared using the Chi-square test.
Differences between treatment and no treatment in the
same subjects were analyzed by Wilcoxon signed-rank test.
A p value < 0.05 was considered statistically significant.
Results
The clinical characteristics of healthy controls and patients
with severe sepsis are shown in Table 1. The mean age of
patients was higher than that of controls. Plasma IL-6, IL-
10, and IL-17 levels in patients with severe sepsis were
significantly higher than those in healthy controls. PlasmaTable 1 Clinical characteristics of healthy controls and patien
mean).
Controls
(n Z 25)
All patien
(n Z 52)
Age (y) 60.72  2.04 72.31 
Male (%) 19 (76) 28 (54)
APACHE II score 24.38 
History (%)
COPD 8 (15)
Heart failure 2 (4)
Pneumoconiosis 3 (6)
Hypertension 24 (46)
Diabetes mellitus 24 (46)
Old CVA 22 (42)
ESRD 8 (15)
Liver cirrhosis 2 (4)
Active malignancy 3 (6)
Infection source
Pneumonia 44 (85)
UTI 3 (6)
Other 5 (9)
Adverse event
New arrhythmia 4 (8)
GI bleeding 11 (21)
Acute renal failure 22 (42)
Shock 28 (54)
Thrombocytopenia 16 (31)
Jaundice 5 (10)
Bacteremia 15 (29)
Plasma level, pg/mL
IL-6 4.23  2.56 179.87 
IL-10 6.50  2.03 98.14 
IL-12 81.73  20.50 106.80 
IL-17 0.97  0.67 3.59  1
TGF-b1 3384.06  358.04 3015.33 
APACHE Z Acute Physiology and Chronic Health Evaluation; COPD Z
accident; ESRD Z end-stage renal disease; GI Z gastrointestinal; IL
tract infection.
a p < 0.05 compared with controls by ManneWhitney U test.
b p < 0.05 compared with survivors by ManneWhitney U test.IL-12 and TGF-b1 levels were similar between control and
patient groups. There was no difference in age, sex,
APACHE II score, history, and adverse event between sur-
vivors and nonsurvivors with severe sepsis. Plasma IL-6 level
in nonsurvivors was higher than that in survivors. Plasma IL-
10, IL-12, IL-17, and TGF-b1 levels were similar among
survivors and nonsurvivors.
Table 2 shows cell analysis in PBMCs between healthy
controls and patients with severe sepsis. Compared with
controls, percentages of CD8þ and CD4þ lymphocytes in
PBMCs of patients were significantly decreased. Monocyte
percentage in PBMCs was similar among controls and pa-
tients. Percentage of Th17 cells in CD4þ lymphocytes in
patients was higher than that in controls. Percentages of
Th1, Th2, and Treg cells in CD4
þ lymphocytes did not differ
between the control and patient groups.
IL-6 production from PBMCs was significantly increased
after LPS stimulation (Fig. 1) in both control and patientts with severe sepsis (number, mean  standard error of the
ts Survivors
(n Z 38)
Nonsurvivors
(n Z 14)
1.72* 71.11  2.10 75.57  2.79
22 6
0.86 23.39  0.96 27.07  1.71
4 (11) 4 (29)
2 (5) 0 (0)
1 (3) 2 (14)
17 (45) 7 (50)
18 (47) 6 (43)
17 (45) 5 (36)
5 (13) 3 (21)
1 (3) 1 (7)
2 (5) 1 (7)
33 (87) 11 (79)
3 (8) 0 (0)
2 (5) 3 (21)
3 (8) 1 (7)
9 (24) 2 (14)
14 (37) 8 (57)
19 (50) 9 (64)
11 (29) 5 (36)
2 (5) 3 (21)
11 (29) 4 (29)
24.89a 145.60  26.71 272.91  51.06b
29.20a 92.82  30.59 112.58  71.94
24.76 121.32  33.41 67.37  11.94
.11a 3.12  1.06 4.85  3.01
209.97 3200.20  263.02 2513.52  285.43
chronic obstructive pulmonary disease; CVA Z cerebral vascular
Z interleukin; TGF Z transforming growth factor; UTI Z urinary
Table 2 Cell analysis in peripheral blood mononuclear
cells between healthy controls and patients with severe
sepsis (mean  standard error of the mean).
Controls
(n Z 25)
Patients
(n Z 52)
Monocytes, % 4.03  0.36 5.53  0.76
CD8þ lymphocytes, % 9.32  1.15 2.67  0.35a
CD4þ lymphocytes, % 18.54  1.33 5.59  0.75a
Th1 cells in CD4þ cells, % 59.49  3.61 50.20  3.38
Th2 cells in CD4þ cells, % 8.83  1.39 9.96  1.29
Th17 cells in CD4þ cells, % 8.08  2.26 21.94  2.77a
Treg cells in CD4
þ cells, % 12.00  1.00 11.22  1.26
Th Z T helper; Treg Z regulatory T.
a p < 0.05 compared with controls by ManneWhitney U test.
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affect IL-6 production from LPS-stimulated PBMCs in both
the control and patient groups.
IL-10 production from PBMCs was significantly
increased after LPS stimulation (Fig. 2) in both the control
and patient groups. Additional anti-IL-17 treatment
significantly increased IL-10 production from LPS-
stimulated PBMCs in both the control and patient
groups. Additional rhIL-17 treatment did not affect IL-10Figure 1 Mean error bars  one standard error mean of interle
mononuclear cells (PBMCs). Bar C represents nonstimulated cell g
cell group. Bar LPS þ anti-IL-17 represents cell group of
LPS þ recombinant human (rh)IL-17 represents cell group of LPS-
from PBMCs was significantly increased after LPS stimulation in
stimulated PBMCs was not affected after additional anti-IL-17
*p < 0.05 compared with C group.production from LPS-stimulated PBMCs in both the con-
trol and patient groups.
IL-12 production from PBMCs was significantly increased
after LPS stimulation (Fig. 3) in both the control and patient
groups. Additional anti-IL-17 treatment significantly
decreased IL-12 production from LPS-stimulated PBMCs in
both the control and patient groups. Additional rhIL-17
treatment significantly increased IL-12 production from
LPS-stimulated PBMCs in both the control and patient
groups.
TGF-b1 production from PBMCs was similar among groups
of nonstimulation, LPS stimulation, LPS stimulation com-
bined with anti-IL-17 treatment, and LPS stimulation com-
bined with rhIL-17 treatment in both the control and
patient groups (Fig. 4).
There was no difference in IL-6, IL-10, IL-12, and TGF-b1
levels from cultured LPS-stimulated PBMCs after anti-IL-17
or rh-IL-17 treatments between survivors and nonsurvivors
(Table 3).
Discussion
This study first found that loss of IL-17 resulted in increased
IL-10 production from stimulated PBMCs. IL-10 also inhibi-
ted Th17 generation in PBMCs culture of healthy donors.19
Thus, low IL-17 response was associated with IL-10 over-
production, which might further inhibit Th17 generation.ukin (IL)-6 level in supernatant of cultured peripheral blood
roup. Bar lipopolysaccharide (LPS) represents LPS-stimulated
LPS-stimulation combined with anti-IL-17 treatment. Bar
stimulation combined with rhIL-17 treatment. IL-6 production
both control and patient groups. IL-6 production from LPS-
or rhIL-17 treatment in both control and patient groups.
Figure 2 Mean error bars  one standard error mean of interleukin (IL)-10 level in supernatant of cultured peripheral blood
mononuclear cells (PBMCs). Bar C represents nonstimulated cell group. Bar lipopolysaccharide (LPS) represents LPS-stimulated cell
group. Bar LPS þ anti-IL-17 represents cell group of LPS-stimulation combined with anti-IL-17 treatment. Bar LPS þ recombinant
human (rh)IL-17 represents cell group of LPS-stimulation combined with rhIL-17 treatment. IL-10 production from PBMCs was
significantly increased after LPS stimulation in both control and patient groups. IL-10 production from LPS-stimulated PBMCs was
significantly increased after additional anti-IL-17 treatment in both control and patient groups. IL-10 production from LPS-
stimulated PBMCs was not affected after additional rhIL-17 treatment in both control and patient groups. *p < 0.05 compared
with C group. **p < 0.05 compared with LPS and LPS þ rhIL-17 groups.
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found in nonsurvivors with severe sepsis.20 Also, persistent
high plasma IL-10 level without a decrease was associated
with mortality in patients with severe sepsis.12 All of the
aforementioned findings suggest that IL-17 was important in
surviving severe sepsis through inhibiting overproduction of
IL-10.
In this work, IL-12 production from stimulated PBMCs of
patients with sepsis and controls was decreased without the
presence of IL-17. Survivors with severe sepsis produced
more IL-12 from stimulated PBMCs than nonsurvivors.20 IL-
12 production from stimulated PBMCs was also increased
after 6 days in survivors with severe sepsis.12 Most IL-12 is
released from activated monocyte/macrophage. IL-12 can
enhance native T lymphocyte differentiation to Th1 cells.
Th1 cells produce IFN-g, which modulates activation of
monocyte/macrophage and NK cell, stimulates B cells to
secrete immunoglobulin, and enhances Th1 cell differen-
tiation. Thus, increase of IL-12 production in patients with
severe sepsis may exert a protective effect, which may be
related to increased cellular immunity and phagocytic
functions. All of the aforementioned factors indicate that
patients with severe sepsis might have poor outcome if they
lose the help of IL-17.
Although additional IL-17 treatment increased IL-12
production from stimulated PBMCs, the median IL-12 in-
crease with IL-17 treatment was < 10 pg/mL. Thissuggests that enhancement of IL-12 production by an in-
crease of IL-17 was limited. IL-17 might also play a
negative regulatory role on IL-12 response.21 Treatment of
IL-17 decreased IL-12einduced IFN-g production in PBMCs.
The decreased IFN-g production was associated with a 60%
decrease in IL-12Rb2 messenger RNA expression. Maybe
the cause of low IL-12 increase from stimulated PBMCs
after IL-17 treatment was low IFN-g expression, which
results in monocyte/macrophage dysfunction. However,
IL-12 significantly decreased IL-17 release from in vitro
mouse splenocytes in a dose-dependent manner.22 IL-12
and IL-17 might have negatively regulatory roles with re-
gard to each other.
Sepsis deeply disturbs immune balance by inducing an
initial systemic inflammatory response and accompanying
an anti-inflammatory process as negative feedback. This
compensatory anti-inflammatory response secondly be-
comes harmful as nearly all immune functions are
compromised.23 This prolonged secondary anti-
inflammatory response might worsen outcome and played
a major role in the decreased defense to nosocomial in-
fections in survivors with sepsis after initial resuscitation
and management.
In the study by Flierl et al,9 anti-IL-17A treatment
increased survival rate in mice of septic peritonitis by CLP.
The protective effect was associated with decreased
plasma systemic proinflammatory cytokines and
Figure 3 Mean error bars  one standard error mean of interleukin (IL)-12 level in supernatant of cultured peripheral blood
mononuclear cells (PBMCs). Bar C represents nonstimulated cell group. Bar lipopolysaccharide (LPS) represents LPS-stimulated
cell group. Bar LPS þ anti-IL-17 represents cell group of LPS-stimulation combined with anti-IL-17 treatment. Bar
LPS þ recombinant human (rh)IL-17 represents cell group of LPS-stimulation combined with rhIL-17 treatment. IL-12 production
from PBMCs was significantly increased after LPS stimulation in both control and patient groups. IL-12 production from LPS-
stimulated PBMCs was significantly decreased after additional anti-IL-17 treatment in both control and patient groups. IL-12
production from LPS-stimulated PBMCs was increased after additional rhIL-17 treatment in both control and patient groups.
*p < 0.05 compared with C group. **p < 0.05 compared with LPS and LPS þ rhIL-17 groups. ***p < 0.05 compared with LPS and
LPS þ anti-IL-17 groups.
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vival rate of IL-17A knockout (KO) mice.24 Compared with
wild-type mice, IL-17A KO mice had a more severe degree
of acute lung injury. The results of these two studies are
conflicting in animal models. Perhaps, in the early stage of
sepsis, IL-17A blockade could decrease systemic inflam-
mation and help patient survival after successful initial
resuscitation. In the late stage of sepsis, the presence of IL-
17 might improve severe sepsis because of decreasing
prolonged secondarily anti-inflammatory response by pre-
venting IL-10 overproduction.
In this work, cytokine (IL-6, IL-10, IL-12, and TGF-b1)
levels from cultured LPS-stimulated PBMCs with anti-IL-17
or rh-IL-17 treatments between survivors and nonsurvivors
did not differ. This suggests that IL-17 might play a role in
the regulating IL-10 and IL-12 from PBMCs. But this regu-
lation after patient admission to the ICU was not related to
patient survival. In patients with severe sepsis, absolute
circulatory counts of Th17 lymphocytes in survivors were
higher than in nonsurvivors.18 Furthermore, Th17/CD4þ
ratio and absolute circulatory Th17 lymphocyte counts in
survivors were increased after 6 days. Whatever studies are
animal or human models, Th17 cells and IL-17 play key roles
in sepsis.
There are two limitations that should be highlighted
with regard to this study. First, the treatment dose ofrhIL-17 and anti-IL-17 each only had one concentration.
The effect of applying different doses of rhIL-17 and anti-
IL-17 were not determined. Thus, the dose-dependent
effect of IL-17 remains unknown. Second, cytokine re-
sponses with rhIL-17 or anti-IL-17 treatments were not
measured after 1 week or more of admission. Maybe the
effects of rhIL-17 or anti-IL-17 in IL-10 and IL-12 responses
from stimulated PBMCs of patients in the late stage of
severe sepsis were different from early stage. If the
regulation of IL-10 and IL-12 production with IL-17 in the
late stage of severe sepsis was associated with final sur-
vival, immune therapy regarding IL-17 might become the
candidate treatment. Another minor concern is that the
mean age of healthy controls is younger than that of pa-
tients with severe sepsis. However, the design of this work
is a comparison between no treatment and treatment in
the same participant. The influence of unequal age be-
tween healthy controls and patients with severe sepsis is
eliminated.
In conclusion, absence of IL-17 resulted in high IL-10
and low IL-12 production from LPS stimulated PBMCs in
patients with sepsis and healthy controls. In patients who
survived at the early stage of severe sepsis, loss of IL-17
help might deteriorate the immune imbalance in the late
stage. Thus, IL-17 response plays an important role in se-
vere sepsis.
Figure 4 Mean error bars  one standard error mean of transforming growth factor (TGF)-beta1 level in supernatant of cultured
peripheral blood mononuclear cells (PBMCs). Bar C represents unstimulated cell group. Bar lipopolysaccharide (LPS) represents
LPS-stimulated cell group. Bar LPS þ anti-IL-17 represents cell group of LPS-stimulation combined with anti-IL-17 treatment. Bar
LPS þ recombinant human (rh)IL-17 represents cell group of LPS-stimulation combined with rhIL-17 treatment. TGF-beta1 pro-
duction from PBMCs was not affected by the treatments of LPS, LPS with anti-IL-17, and LPS with rhIL-17.
Table 3 Cytokine levels from cultured
lipopolysaccharide-stimulated peripheral blood mono-
nuclear cells after treatments between survivors and
nonsurvivors.
Cytokine levels (pg/mL) Survivors
(n Z 38)
Nonsurvivors
(n Z 14)
IL-6
Anti-IL-17 426.97  15.36 482.93  32.44
rhIL-17 435.53  16.67 486.97  34.35
IL-10
Anti-IL-17 272.71  34.93 286.58  84.99
rhIL-17 182.67  26.20 199.90  66.77
IL-12
Anti-IL-17 251.79  50.49 304.34  74.71
rhIL-17 341.01  65.94 409.49  110.43
Transforming growth factor-b1
Anti-IL-17 357.98  30.43 332.85  30.00
rhIL-17 356.20  29.61 368.40  44.35
IL Z interleukin; rh Z recombinant human.
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